Cite

HARVARD Citation

    Buchbinder, E. et al. (2019). Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. Journal for immunotherapy of cancer. 7 (1), p. . [Online]. 
  
Back to record